Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 541,835	$ 373,173
Accounts receivable, net of allowances of approximately $2.9 million and $17.6 million at December 31, 2016 and 2015, respectively	22,087	52,328
Inventory, net	70,898	64,584
Prepaid expenses and other current assets	19,133	19,995
Current assets held for sale	0	322,837
Total current assets	653,953	832,917
Fixed assets, net	30,961	34,780
Intangible assets not subject to amortization	253,620	253,620
Amortizable intangible assets	361,601	382,600
Goodwill	255,629	289,441
Restricted cash	5,032	1,428
Contingent purchase price from sale of businesses	143,700	0
Other assets	715	730
Total assets	1,705,211	1,795,516
Current liabilities:
Accounts payable	28,450	36,038
Accrued expenses	88,524	128,558
Current portion of contingent purchase price	55,000	26,800
Convertible senior notes	53,749	255,473
Deferred revenue	18,902	19,863
Current liabilities held for sale	0	67,515
Total current liabilities	244,625	534,247
Contingent purchase price	82,289	96,957
Convertible senior notes	623,584	312,107
Deferred tax liabilities	89,992	89,996
Other liabilities	11,705	13,346
Total liabilities	1,052,195	1,046,653
Equity component of currently redeemable convertible senior notes (Note 10)	1,033	17,089
Stockholders’ equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 187,500,000 authorized; 73,212,545 issued and 71,019,563 outstanding at December 31, 2016 and 71,767,371 issued and 69,574,389 outstanding at December 31, 2015	73	72
Additional paid-in capital	1,256,890	1,208,058
Treasury stock, at cost; 2,192,982 shares at December 31, 2016 and December 31, 2015	(50,000)	(50,000)
Accumulated deficit	(548,983)	(429,865)
Accumulated other comprehensive (loss) income	(5,479)	3,973
Total The Medicines Company stockholders’ equity	652,501	732,238
Non-controlling interest in joint venture	(518)	(464)
Total stockholders’ equity	651,983	731,774
Total liabilities and stockholders’ equity	1,705,211	1,795,516
In-process research and development [Member]
Current assets:
Intangible assets not subject to amortization	253,620	253,620
Product licenses [Member]
Current assets:
Amortizable intangible assets	26,987	23,631
Developed product rights [Member]
Current assets:
Amortizable intangible assets	$ 334,614	$ 358,969